Readoutin 163d
Takeda — Zasocitinib
Phase 3 primary completion: A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines.
- Date
- May 2027
- Type
- Readout
- Indication
- Psoriatic Arthritis
Readoutin 163d
Phase 3 primary completion: A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.